Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 科学研究和技术服务业
Company Introduction 上海皓元医药股份有限公司成立于2006年，位于上海张江生物医药基地，专注于小分子药物发现领域的分子砌块和工具化合物的研究开发，以及小分子药物原料药、中间体的工艺开发和生产技术改进，是一家为全球医药企业和科研机构提供从药物发现到原料药和医药中间体的规模化生产的相关产品和技术服务的高新技术企业。公司荣获了上海市“专精特新”企业、上海市小巨人企业、上海市品牌培育示范企业、上海市专利工作试点企业、浦东新区企业研发机构等多项荣誉称号。 皓元医药扎根生物医药领域，始终坚持自主科技创新，勇于挑战技术难点。历经多年的技术积累和行业沉淀，形成了包含高活性原料药（HPAPI）开发平台、多手性复杂药物技术平台、维生素D衍生物药物原料药研发平台、特色靶向药物开发平台、药物固态化学研究技术平台、分子砌块和工具化合物库开发孵化平台在内的6个核心技术平台，服务范围涵盖抗肿瘤、抗病毒、糖尿病、心脑血管、免疫系统、神经系统等治疗领域。为提升创新效能，公司不断加大对硬件设施设备的投入，配备了先进的科研设施及生产设施，建立了千克级GMP条件实验室和医药研发中心，在香港、美国均设立了商务中心。 公司坚信人才驱动创新，注重人才队伍建设，核心技术骨干团队技术水平高、创新能力强、实践经验丰富，累积申请专利百余项。 皓元医药坚持“一切为了客户，一切源于创新”的服务宗旨，密切关注全球生物医药产业的发展趋势，发挥现有的技术优势和资源优势，深耕小分子药物研发服务与产业化应用市场。目前，皓元医药与亚洲、欧洲、美洲、大洋洲等多个地区的知名医药企业、科研院所、CRO公司建立了深度合作关系，承载着来自全球3000多家合作伙伴的研发创新项目，致力于推动研发创新以改善全球病患的生存状态和生活质量。公司力争在未来成为具有国际竞争力的、世界一流的医药研发和生产服务企业，让药物研发更高效，更快上市，更早惠及人类健康。
Main Business 小分子药物发现领域的分子砌块和工具化合物的研发，以及小分子药物原料药、中间体的工艺开发和生产技术改进，为全球医药企业和科研机构提供从药物发现到原料药和医药中间体的规模化生产的相关产品和技术服务。
Legal Representative 郑保富
Top Executives
董事长：郑保富
董事：Xiaodan Gu,高强,李硕梁,陈韵,金飞敏
独立董事：张兴贤,高垚,袁彬
Top 5 Shareholder
Shareholder name Nature Holding Date
上海安戌信息科技有限公司流通A股32.34%30/09/2024
君信（上海）股权投资基金管理有限公司－苏民投君信（上海）产业升级与科技创新股权投资合伙企业（有限合伙）流通A股7.14%30/09/2024
上海臣骁企业管理咨询中心（有限合伙）流通A股3.98%30/09/2024
香港中央结算有限公司流通A股3.50%30/09/2024
深圳盈富汇智私募证券基金有限公司－盈富增信添利26号私募证券投资基金流通A股2.70%30/09/2024
Company Secretary 沈卫红
Solicitors 北京德恒律师事务所
Auditors 容诚会计师事务所（特殊普通合伙）
Tel No 021-58338205
Fax No 021-58955996
Website www.chemexpress.com.cn
Email hy@chemexpress.com.cn
Company Address
Register: 中国（上海）自由贸易试验区蔡伦路720弄2号501室
Office: 上海市浦东新区张衡路1999弄3幢
Listing Date 08/06/2021
Shares Capital
Shares Capital: 210,928,884
Total A Share: 210,928,884
Listed A Share: 206,149,949
Non-tradable A Share: 4,778,935
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.850
DPS(RMB)* ¥ 0.150
NBV Per Share(RMB)* ¥ 16.684
Market Capitalization(RMB) 7.679B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.